This past weekend, seven members of Texas Retina’s research team were invited to attend the Ollin Study Coordinators meeting in Maui, Hawaii. Ollin is a Phase Ib study of two different formulations of intravitreal OLN324 in adults with either diabetic macular edema (DME) or wet age-related macular degeneration (AMD). Texas Retina’s Dallas Main, Arlington and Plano offices are participating in the study, and enrollment closed July 18, 2025.
At the meeting, attendees discussed the study processes and milestones and learned more about the medication, including nonclinical studies and preparation for seeking U.S. Food and Drug Administration (FDA) approval.
The following Texas Retina research team members attended the Ollin study meeting:
- Melissa Alva, Lead Study Coordinator – Arlington
- Kal Agdie, Lead Study Coordinator – Dallas Main
- Laurie Griffis, Lead Study Coordinator – Plano
- Paige Abril, Research Coordinator – Dallas Main
- Tony Abate, Diagnostic Technician – Dallas Main
- Reena Ghatahora, Clinical Trial Assistant – Plano
- Carla Peak, Research Coordinator – Plano
Dr. Wayne Solley serves as the study’s Principal Investigator for Arlington, Dr. Ashkan Abbey for Dallas Main, and Dr. Lori Coors for Plano.
Click HERE to learn more about all the clinical trials currently available at Texas Retina.